Leronlimab has received over 830 patients, some have been on it for 5 years, there is no SAE, and this is most important for the FDA, so in cancers trials we get Phase II immediately and they have to go from Phase I, these are the differences. After 12 months of 9 patients, only 4 remained on their treatment.